Cargando…
An economic evaluation of the healthcare cost of tinnitus management in the UK
BACKGROUND: There is no standard treatment pathway for tinnitus patients in the UK. Possible therapies include education and reassurance, cognitive behavioural therapies, modified tinnitus retraining therapy (education and sound enrichment), or amplification of external sound using hearing aids. How...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567641/ https://www.ncbi.nlm.nih.gov/pubmed/28830503 http://dx.doi.org/10.1186/s12913-017-2527-2 |
_version_ | 1783258755515809792 |
---|---|
author | Stockdale, David McFerran, Don Brazier, Peter Pritchard, Clive Kay, Tony Dowrick, Christopher Hoare, Derek J |
author_facet | Stockdale, David McFerran, Don Brazier, Peter Pritchard, Clive Kay, Tony Dowrick, Christopher Hoare, Derek J |
author_sort | Stockdale, David |
collection | PubMed |
description | BACKGROUND: There is no standard treatment pathway for tinnitus patients in the UK. Possible therapies include education and reassurance, cognitive behavioural therapies, modified tinnitus retraining therapy (education and sound enrichment), or amplification of external sound using hearing aids. However, the effectiveness of most therapies is somewhat controversial. As health services come under economic pressure to deploy resources more effectively there is an increasing need to demonstrate the value of tinnitus therapies, and how value may be continuously enhanced. The objective of this project was to map out existing clinical practice, estimate the NHS costs associated with the management approaches used, and obtain initial indicative estimates of cost-effectiveness. METHODS: Current treatment pathways, costs and health outcomes were determined from the tinnitus literature, national statistics, a patient survey, and expert opinion. These were used to create an Excel-based economic model of therapy options for tinnitus patients. The probabilities associated with the likelihood of an individual patient receiving a particular combination of therapies was used to calculate the average cost of treatment per patient, average health outcome per patient measured in QALYs gained, and cost-effectiveness, measured by the average cost per QALY gained. RESULTS: The average cost of tinnitus treatment per patient per year is GB£717, equating to an NHS healthcare bill of GB£750 million per year. Across all pathways, tinnitus therapy costs £10,600 per QALY gained. Results were relatively insensitive to restrictions on access to cognitive behaviour therapy, and a subsequent reliance on other therapies. CONCLUSIONS: NHS provisions for tinnitus are cost-effective against the National Institute for Health and Care Excellence cost-effective threshold. Most interventions help, but education alone offers very small QALY gains. The most cost-effective therapies in the model were delivered within audiology. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-017-2527-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5567641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55676412017-08-29 An economic evaluation of the healthcare cost of tinnitus management in the UK Stockdale, David McFerran, Don Brazier, Peter Pritchard, Clive Kay, Tony Dowrick, Christopher Hoare, Derek J BMC Health Serv Res Research Article BACKGROUND: There is no standard treatment pathway for tinnitus patients in the UK. Possible therapies include education and reassurance, cognitive behavioural therapies, modified tinnitus retraining therapy (education and sound enrichment), or amplification of external sound using hearing aids. However, the effectiveness of most therapies is somewhat controversial. As health services come under economic pressure to deploy resources more effectively there is an increasing need to demonstrate the value of tinnitus therapies, and how value may be continuously enhanced. The objective of this project was to map out existing clinical practice, estimate the NHS costs associated with the management approaches used, and obtain initial indicative estimates of cost-effectiveness. METHODS: Current treatment pathways, costs and health outcomes were determined from the tinnitus literature, national statistics, a patient survey, and expert opinion. These were used to create an Excel-based economic model of therapy options for tinnitus patients. The probabilities associated with the likelihood of an individual patient receiving a particular combination of therapies was used to calculate the average cost of treatment per patient, average health outcome per patient measured in QALYs gained, and cost-effectiveness, measured by the average cost per QALY gained. RESULTS: The average cost of tinnitus treatment per patient per year is GB£717, equating to an NHS healthcare bill of GB£750 million per year. Across all pathways, tinnitus therapy costs £10,600 per QALY gained. Results were relatively insensitive to restrictions on access to cognitive behaviour therapy, and a subsequent reliance on other therapies. CONCLUSIONS: NHS provisions for tinnitus are cost-effective against the National Institute for Health and Care Excellence cost-effective threshold. Most interventions help, but education alone offers very small QALY gains. The most cost-effective therapies in the model were delivered within audiology. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-017-2527-2) contains supplementary material, which is available to authorized users. BioMed Central 2017-08-22 /pmc/articles/PMC5567641/ /pubmed/28830503 http://dx.doi.org/10.1186/s12913-017-2527-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Stockdale, David McFerran, Don Brazier, Peter Pritchard, Clive Kay, Tony Dowrick, Christopher Hoare, Derek J An economic evaluation of the healthcare cost of tinnitus management in the UK |
title | An economic evaluation of the healthcare cost of tinnitus management in the UK |
title_full | An economic evaluation of the healthcare cost of tinnitus management in the UK |
title_fullStr | An economic evaluation of the healthcare cost of tinnitus management in the UK |
title_full_unstemmed | An economic evaluation of the healthcare cost of tinnitus management in the UK |
title_short | An economic evaluation of the healthcare cost of tinnitus management in the UK |
title_sort | economic evaluation of the healthcare cost of tinnitus management in the uk |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567641/ https://www.ncbi.nlm.nih.gov/pubmed/28830503 http://dx.doi.org/10.1186/s12913-017-2527-2 |
work_keys_str_mv | AT stockdaledavid aneconomicevaluationofthehealthcarecostoftinnitusmanagementintheuk AT mcferrandon aneconomicevaluationofthehealthcarecostoftinnitusmanagementintheuk AT brazierpeter aneconomicevaluationofthehealthcarecostoftinnitusmanagementintheuk AT pritchardclive aneconomicevaluationofthehealthcarecostoftinnitusmanagementintheuk AT kaytony aneconomicevaluationofthehealthcarecostoftinnitusmanagementintheuk AT dowrickchristopher aneconomicevaluationofthehealthcarecostoftinnitusmanagementintheuk AT hoarederekj aneconomicevaluationofthehealthcarecostoftinnitusmanagementintheuk AT stockdaledavid economicevaluationofthehealthcarecostoftinnitusmanagementintheuk AT mcferrandon economicevaluationofthehealthcarecostoftinnitusmanagementintheuk AT brazierpeter economicevaluationofthehealthcarecostoftinnitusmanagementintheuk AT pritchardclive economicevaluationofthehealthcarecostoftinnitusmanagementintheuk AT kaytony economicevaluationofthehealthcarecostoftinnitusmanagementintheuk AT dowrickchristopher economicevaluationofthehealthcarecostoftinnitusmanagementintheuk AT hoarederekj economicevaluationofthehealthcarecostoftinnitusmanagementintheuk |